- Home
- Equipment
- north america
- tumor specificity
Refine by
Tumor Specificity Equipment Supplied In North America
55 equipment items found
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, ...
Manufactured by:Scytek Laboratories Inc based inLogan, UT 84321, UTAH (USA)
Species: Mouse,Immunogen: Synthetic peptide corresponding to aa 1-24 of human ACTH ,Clone: 2F6 Isotype: IgG1, kappa, Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this ...
Manufactured by:NexImmune, Inc. based inGaithersburg, MARYLAND (USA)
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease. An AIM™ Adoptive Cellular Therapy (ACT) product is manufactured using an AIM™ nanoparticle cocktail ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many ...
Manufactured by:Scytek Laboratories Inc based inLogan, UT 84321, UTAH (USA)
Species: Mouse, Immunogen: N-terminal fragment of human ACTH conjugated to KLH,Clone: 57,Isotype: IgG1, kappa, Species Reactivity: Human and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not ...
Manufactured by:Scytek Laboratories Inc based inLogan, UT 84321, UTAH (USA)
Species: Mouse,Immunogen: Synthetic peptide corresponding to aa 1-24 of human ACTH, Clone: AH26, Isotype: IgG1, kappa, Species Reactivity: Human, Mouse and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this ...
Manufactured by:Tactiva Therapeutics based inBuffalo, NEW YORK (USA)
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune cells are manufactured in a ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After infusion and adsorption onto targeted cancer cells facilitated by the cancer-specific monoclonal ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The ...
Manufactured by:Kaio Therapy, LLC based inRaleigh, NORTH CAROLINA (USA)
Kaio Therapy's Immune Activation Heat Therapy is a novel hyperthermia system that delivers precisely controlled heat at the cellular level within a tumor. Because Kaio’s IAHT elegantly induces necrosis while activating a systemic, tumor specific response, it can also serve as a platform for other immunotherapies seeking higher efficacies, ...
by:NeoGenomics Laboratories based inFort Myers, FLORIDA (USA)
RaDaR™ is a personalized, multi-tumor liquid biopsy assay that can track a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. This allows RaDaR™ to detect traces of molecular residual disease (MRD) in a patient following surgery or other treatment for cancer, enabling early ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.3 Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta T cells. The Company ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for novel small molecule PRMT5 ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. This target has an attractive safety profile based on in vivo studies and knock out mouse studies. ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...